Teva

Teva Pharmaceutical Industries will unveil its “Pivot to Growth” strategy and financial outlook through 2030 at the J.P. Morgan Healthcare Conference. The company aims to transform into a leading biopharmaceutical entity, leveraging its generics business and innovative pipeline.

For 2025, Teva projects revenues of $16.8–$17.0 billion, with substantial free cash flow and EBITDA targets. Looking ahead, it aims for mid-single-digit revenue CAGR by 2030 and over $3.5 billion in free cash flow, alongside reduced net leverage and an investment-grade credit rating. While near-term revenue may be flat, the strategy emphasizes pipeline advancement and financial discipline.

Teva Pharmaceutical Industries has received upgraded credit ratings and a positive outlook from S&P and Moody’s. These actions reflect the company’s successful “Pivot to Growth” strategy, evidenced by consistent deleveraging and a return to revenue growth. Strong performance in branded medicines and upcoming biosimilar launches are key drivers, offsetting generics headwinds. This signifies Teva’s progress toward financial health and potentially investment-grade status.